Study guide

5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care

EBP-EAP Examination in Paediatrics Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding

EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)

2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity

Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections

Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

4 Chapter 4: Acute Paediatric Emergencies & Critical Care

EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination

5 Chapter 5: Paediatric Respiratory Medicine

Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

6 Chapter 6: Paediatric Cardiology

Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism

Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health

Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy

11 Chapter 11: Paediatric Haematology & Oncology

Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia

12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy

Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions

The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia

14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics

Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

15 Chapter 15: Paediatric Ophthalmology & ENT Disorders

Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions

16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health

Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance

17 Chapter 17: Adolescent Medicine & Healthcare Transition

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition

18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics

Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics

19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine

Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy

5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care

Key Takeaways Explain This Topic AI

For tonic-clonic status epilepticus, ILAE t1 is 5 minutes: initiate emergency treatment. The approximate t2 of 30 minutes marks the risk of long-term neuronal injury and network changes during continuing seizures; it is not a guaranteed injury threshold.

First-line emergency benzodiazepine therapy consists of buccal midazolam (0.5 mg/kg, max 10 mg) or rectal diazepam (0.5 mg/kg) in the absence of vascular access, or IV lorazepam (0.1 mg/kg, max 4 mg); a single repeat dose may be given at 10 minutes if seizures persist.

No more than two total doses of benzodiazepines should ever be administered before progressing to second-line non-sedating anticonvulsants, minimizing the risk of respiratory arrest and critical airway loss.

Second-line intravenous options include levetiracetam (60 mg/kg), fosphenytoin (20 mg PE/kg) or phenytoin (20 mg/kg), or sodium valproate (40 mg/kg); valproate is strictly contraindicated in children with suspected mitochondrial or metabolic disorders due to fatal hepatic necrosis. Do not use valproate when pregnancy is possible.

For seizures continuing despite adequate benzodiazepines and a second-line drug, involve PICU/anaesthesia early, prepare for intubation at 30 minutes and start anaesthesia no later than 40 minutes. Intubate earlier for airway or ventilatory failure; use continuous EEG to guide refractory treatment.

Last updated: November 2026

Paediatric Status Epilepticus: Time-Critical Resuscitation and Anticonvulsant Protocols

Paediatric status epilepticus (SE) is one of the most common, time-critical neurological emergencies encountered in paediatrics. It is associated with significant potential morbidity, including permanent cognitive impairment, secondary epileptogenesis, and mortality. The physiological foundation of modern status epilepticus management rests on one absolute axiom: time is brain . With every passing minute of sustained epileptic activity, intrinsic inhibitory mechanisms fail, anticonvulsant drugs lose molecular efficacy, and the risk of irreversible neuronal injury escalates exponentially.

Modern Definition and Conceptual Framework: The ILAE Two-Time-Point Paradigm

The International League Against Epilepsy (ILAE) defines status epilepticus through a dual-time-point framework: t 1 (Time Point 1) = 5 minutes → Operational threshold: initiate emergency pharmacological therapy t 2 (Time Point 2) = 30 minutes → Approximate threshold for risk of long-term neuronal injury \begin{aligned}

\mathbf{t_1 \text{ (Time Point 1)}} &= 5 \text{ minutes} \quad \rightarrow \quad \text{Operational threshold: initiate emergency pharmacological therapy} \\

\mathbf{t_2 \text{ (Time Point 2)}} &= 30 \text{ minutes} \quad \rightarrow \quad \text{Approximate threshold for risk of long-term neuronal injury}

\end{aligned} t 1 ​ (Time Point 1) t 2 ​ (Time Point 2) ​ = 5 minutes → Operational threshold: initiate emergency pharmacological therapy = 30 minutes → Approximate threshold for risk of long-term neuronal injury ​

Operational Time Point ( t 1 = 5 minutes t_1 = 5\text{ minutes} t 1 ​ = 5 minutes )

Historically, status epilepticus was defined as continuous seizure activity lasting > 30 minutes >30\text{ minutes} > 30 minutes . However, physiological and clinical investigations demonstrated that normal spontaneous generalized convulsive seizures terminate within 2 to 3 minutes . If a convulsive seizure continues beyond 5 minutes , spontaneous termination is highly improbable, and the condition must be treated operationally as early status epilepticus. Emergency pharmacological intervention must be initiated at minute 5.

Long-Term Injury-Risk Time Point ( t 2 = 30 minutes t_2 = 30\text{ minutes} t 2 ​ = 30 minutes )

For continuing tonic-clonic seizures, 30 minutes is the approximate ILAE time point after which long-term consequences may occur, including neuronal injury, neuronal death and network alterations. Excitotoxicity and metabolic stress contribute to injury, but its timing varies with seizure type, cause and duration. This is a risk threshold, not proof of irreversible damage in an individual child. For focal status epilepticus with impaired awareness, t 1 t_1 t 1 ​ is 10 minutes 10\text{ minutes} 10 minutes and t 2 t_2 t 2 ​ is > 60 minutes >60\text{ minutes} > 60 minutes ; for absence status, t 1 t_1 t 1 ​ is 10 to 15 minutes 10\text{ to }15\text{ minutes} 10 to 15 minutes .

Neurobiology of Pharmacoresistance: Why Minutes Matter

The progressive failure of first-line medications during prolonged seizures is explained by dynamic, activity-dependent neuroreceptor trafficking: [Ongoing Seizure Activity (>5-10 min)]

  • |
  • +----------------------------+----------------------------+
  • | |
  • v v
  • [Internalisation of GABA-A Receptors] [Recruitment of NMDA/AMPA Receptors]
  • Synaptic GABA-A receptors undergo - Excitatory glutamate receptors
  • rapid clathrin-mediated endocytosis translocate from intracellular stores
  • Depletion of functional postsynaptic to the postsynaptic membrane
  • inhibitory receptors - Massive intracellular calcium influx
  • | |
  • v v
  • [Benzodiazepines Lose Clinical Efficacy] [Excitotoxic Neuronal Apoptosis & Necrosis]
  • (10- to 20-fold loss of potency in 15 min) (Risk of long-term injury with prolonged SE)

Within minutes of continuous seizure discharge, postsynaptic GABA A \text{GABA}_A GABA A ​ receptors undergo clathrin-dependent endocytosis , disappearing from the synaptic membrane into intracellular endosomes. Because benzodiazepines act as positive allosteric modulators of the GABA A \text{GABA}_A GABA A ​ receptor, their molecular target is progressively removed. By 15 to 30 minutes, benzodiazepines suffer a 10- to 20-fold loss of potency . Simultaneously, excitatory NMDA and AMPA glutamate receptors translocate to the postsynaptic membrane, driving persistent, self-sustaining epileptiform firing and massive calcium-mediated excitotoxicity.

The 5-Minute Time-Critical Anticonvulsant Protocol

Modern European paediatric protocols mandate a structured, time-stamped escalation algorithm:

Resuscitation Phase Timeline Primary Clinical Actions Pharmacological Interventions

Phase 1: Stabilization & Triage 0 to 5 minutes ABCDE assessment, high-flow O 2 O_2 O 2 ​ , recovery position, bedside blood glucose check, ECG/SpO2 Treat hypoglycaemia immediately if present ( D 10 W D10W D 10 W 2 − 5 mL/kg 2-5\text{ mL/kg} 2 − 5 mL/kg ); do not delay drugs for IV attempts

Phase 2: First-Line Anticonvulsant 5 to 10 minutes Confirm seizure duration ≥ 5 \ge 5 ≥ 5 min; administer fast-acting benzodiazepine No IV : Buccal Midazolam ( 0.5 mg/kg 0.5\text{ mg/kg} 0.5 mg/kg ) or Rectal Diazepam ( 0.5 mg/kg 0.5\text{ mg/kg} 0.5 mg/kg ); With IV : IV Lorazepam ( 0.1 mg/kg 0.1\text{ mg/kg} 0.1 mg/kg )

Phase 3: Second Benzodiazepine Dose 10 to 15 minutes Re-evaluate at 10 min; if ongoing, give 2nd dose; call senior paediatrician and PICU/anaesthesia Repeat single benzodiazepine dose; CRITICAL: Maximum 2 doses total before escalating

Phase 4: Second-Line IV Anticonvulsant 15 to 35 minutes Give the second-line drug promptly at its specified rate; involve PICU/anaesthesia early Levetiracetam ( 60 mg/kg 60\text{ mg/kg} 60 mg/kg IV) OR Fosphenytoin ( 20 mg PE/kg 20\text{ mg PE/kg} 20 mg PE/kg IV) or Phenytoin ( 20 mg/kg 20\text{ mg/kg} 20 mg/kg IV) OR Valproate ( 40 mg/kg 40\text{ mg/kg} 40 mg/kg IV)

Phase 5: Refractory Status (RSE) Prepare at 30; anaesthesia by 40 minutes PICU/anaesthesia support, RSI and continuous EEG; earlier airway support if needed Continuous IV Midazolam ( 0.1 − 2 mg/kg/h 0.1-2\text{ mg/kg/h} 0.1 − 2 mg/kg/h ) OR Propofol OR Thiopental burst-suppression

  • Detailed Analysis of Protocol Phases and Drugs
  • Phase 1: 0 to 5 Minutes (Immediate Resuscitation and Metabolic Screen)

Airway and Oxygenation : Place the child in the lateral recovery position. Open the airway with a gentle chin lift or jaw thrust. Administer high-flow 100 % 100\% 100% oxygen via a non-rebreather mask ( 10 to 15 L/min 10\text{ to }15\text{ L/min} 10 to 15 L/min ).

Bedside Capillary Glucose : Check blood glucose immediately . Hypoglycaemia is a reversible cause of status epilepticus and causes irreversible neuronal death if missed. If blood glucose is < 3.0 mmol/L <3.0\text{ mmol/L} < 3.0 mmol/L ( < 54 mg/dL <54\text{ mg/dL} < 54 mg/dL ), administer an immediate intravenous/intraosseous bolus of 10 % 10\% 10% Dextrose at 2 to 5 mL/kg 2\text{ to }5\text{ mL/kg} 2 to 5 mL/kg ( 0.2 to 0.5 g/kg 0.2\text{ to }0.5\text{ g/kg} 0.2 to 0.5 g/kg ). Follow with a continuous dextrose infusion.

Monitoring and Timing : Apply continuous pulse oximetry, 3-lead ECG, and non-invasive blood pressure monitoring. Record the exact time of seizure onset.

Phase 2: 5 to 10 Minutes (First-Line Benzodiazepine Administration)

If convulsive activity persists at 5 minutes , administer the first dose of benzodiazepine without delay:

When Vascular Access is NOT Available (Pre-hospital or Community Setting) :

Buccal Midazolam (First-Line Gold Standard) : Dose is 0.5 mg/kg 0.5\text{ mg/kg} 0.5 mg/kg (maximum single dose 10 mg 10\text{ mg} 10 mg ). Administer half of the liquid into each buccal cavity between the lower gum and cheek. It is rapidly absorbed across the rich buccal venous plexus, achieving therapeutic blood concentrations faster than rectal diazepam with superior clinical cessation rates and greater social dignity.

Rectal Diazepam : Dose is 0.5 mg/kg 0.5\text{ mg/kg} 0.5 mg/kg (maximum single dose 10 mg 10\text{ mg} 10 mg ) via rectal tube.

Intramuscular Midazolam : Dose is 0.2 mg/kg 0.2\text{ mg/kg} 0.2 mg/kg (max 10 mg 10\text{ mg} 10 mg ); highly effective and rapidly absorbed via the vastus lateralis.

When Vascular (IV or IO) Access IS Established :

Intravenous Lorazepam : Dose is 0.1 mg/kg 0.1\text{ mg/kg} 0.1 mg/kg (maximum single dose 4 mg 4\text{ mg} 4 mg ) slow IV push over 2 minutes. Lorazepam is the preferred intravenous agent due to its low lipid solubility relative to diazepam; it does not rapidly redistribute into peripheral adipose tissue, maintaining an effective anticonvulsant duration of action in the brain for 12 to 24 hours .

Alternative : Intravenous Midazolam ( 0.15 to 0.2 mg/kg 0.15\text{ to }0.2\text{ mg/kg} 0.15 to 0.2 mg/kg ) or Intravenous Diazepam ( 0.2 to 0.3 mg/kg 0.2\text{ to }0.3\text{ mg/kg} 0.2 to 0.3 mg/kg ).

Phase 3: 10 to 15 Minutes (Second-Dose Benzodiazepine Evaluation)

If active convulsive seizures continue 5 to 10 minutes after the initial benzodiazepine dose, administer a second, single dose of the same benzodiazepine (or IV lorazepam 0.1 mg/kg 0.1\text{ mg/kg} 0.1 mg/kg if intravenous access has now been secured).

Warning

The Strict "Rule of Two" : Never administer more than two total doses of benzodiazepines (including pre-hospital doses administered by paramedics or parents). Giving three or more doses of benzodiazepines does not improve seizure termination rates, but drastically increases the incidence of severe respiratory depression, upper airway collapse, hypotension, and the requirement for emergency intubation .

Phase 4: 15 to 35 Minutes (Second-Line Non-Sedating IV Anticonvulsants)

If the seizure continues despite two doses of benzodiazepines, the patient has established status epilepticus. Initiate a second-line intravenous anticonvulsant immediately. Three major randomized clinical trials— EcLiPSE (UK), ConSEPT (Australia/NZ), and ESETT (USA)—demonstrated comparable efficacy (approximately 50 % to 60 % 50\%\text{ to }60\% 50% to 60% seizure cessation) among the three primary second-line agents: [Established Status Epilepticus (Seizure >15 min)]

  • |
  • Select Second-Line Non-Sedating IV Anticonvulsant
  • / | \
  • [Levetiracetam] [Phenytoin / Fosphenytoin] [Sodium Valproate]
  • 60 mg/kg IV - PHT: 20 mg/kg IV - 40 mg/kg IV
  • (max 4,500 mg) - Fos: 20 mg PE/kg IV (max 3,000 mg)
  • Infuse over 5-10 min (max 1,000-1,500 mg PHT or PE) - Infuse over 5-10 min
  • Exceptional safety; - PHT over 20 min; Fos per - AVOID in suspected
  • no cardiac telemetry its specific infusion rate Mitochondrial Disease
  • required - Continuous ECG & BP; risk (POLG), urea cycle defects
  • of arrhythmias/extravasation
  • 1. Levetiracetam (Keppra)

Dosing : 60 mg/kg 60\text{ mg/kg} 60 mg/kg IV (maximum dose 4 , 500 mg 4,500\text{ mg} 4 , 500 mg ) infused rapidly over 5 to 10 minutes 5\text{ to }10\text{ minutes} 5 to 10 minutes .

Mechanism : Binds to synaptic vesicle protein SV2A , modulating exocytosis and presynaptic neurotransmitter release.

Clinical Profile : Preferred first choice in modern practice due to its exceptional safety profile: zero cardiovascular toxicity, minimal protein binding, no hepatic CYP450 metabolism (cleared renally), and no requirement for continuous ECG telemetry during infusion.

2. Fosphenytoin / Phenytoin

Dosing :

Phenytoin : 20 mg/kg 20\text{ mg/kg} 20 mg/kg IV (maximum dose 1 , 000 to 1 , 500 mg 1,000\text{ to }1,500\text{ mg} 1 , 000 to 1 , 500 mg ) diluted strictly in 0.9 % 0.9\% 0.9% normal saline (phenytoin precipitates in dextrose solutions!). Maximum infusion rate is 1 mg/kg/min 1\text{ mg/kg/min} 1 mg/kg/min (not to exceed 50 mg/min 50\text{ mg/min} 50 mg/min ); infused over 20 minutes.

Fosphenytoin : Water-soluble prodrug dosed as 20 mg PE/kg 20\text{ mg PE/kg} 20 mg PE/kg (phenytoin sodium equivalents); can be infused up to 3 mg PE/kg/min 3\text{ mg PE/kg/min} 3 mg PE/kg/min ( 150 mg PE/min 150\text{ mg PE/min} 150 mg PE/min ).

Mechanism : Blocks voltage-gated sodium channels, stabilizing the inactive state and preventing high-frequency sustained repetitive firing.

Toxicity & Precautions : Phenytoin requires continuous ECG and blood pressure monitoring throughout the infusion. Rapid infusion causes hypotension, heart block, QRS prolongation, and fatal ventricular arrhythmias . Extravasation causes severe tissue necrosis and purple glove syndrome . Phenytoin is strictly contraindicated in second- or third-degree atrioventricular heart block.

3. Sodium Valproate

Dosing : 40 mg/kg 40\text{ mg/kg} 40 mg/kg IV (maximum dose 3 , 000 mg 3,000\text{ mg} 3 , 000 mg ) infused over 5 to 10 minutes 5\text{ to }10\text{ minutes} 5 to 10 minutes .

Mechanism : Increases brain GABA concentrations via inhibition of GABA transaminase and succinic semialdehyde dehydrogenase, while blocking voltage-gated sodium and T-type calcium channels.

Caution

Critical Contraindication for Valproate : Sodium valproate is strictly contraindicated in any infant or child with known or suspected underlying inborn errors of metabolism, particularly mitochondrial cytopathies (especially Polymerase Gamma [ POLG ] gene mutations such as Alpers-Huttenlocher syndrome), urea cycle disorders, or organic acidemias. Administering valproate to a child with an underlying POLG mutation precipitates fulminant, fatal hepatic necrosis, acute liver failure, and severe hyperammonemic encephalopathy. Do not use valproate when pregnancy is possible ; follow national valproate safety restrictions.

Phase 5: Prepare at 30 Minutes; Anaesthesia by 40 Minutes (Refractory Status)

When clinical or electrographic seizure activity persists despite two doses of benzodiazepines and a full therapeutic dose of a second-line anticonvulsant, the condition is classified as Refractory Status Epilepticus (RSE) . If seizures continue at 30 minutes, prepare for intubation and start anaesthesia no later than 40 minutes. Do not delay airway intervention for respiratory failure while waiting for this treatment stage.

Airway Management : Perform emergent Rapid Sequence Intubation (RSI) using neuroprotective induction agents (e.g., Ketamine 1 to 2 mg/kg 1\text{ to }2\text{ mg/kg} 1 to 2 mg/kg or Propofol 2 to 3 mg/kg 2\text{ to }3\text{ mg/kg} 2 to 3 mg/kg combined with Rocuronium 1.2 mg/kg 1.2\text{ mg/kg} 1.2 mg/kg ). Avoid suxamethonium if prolonged immobility, rhabdomyolysis, hyperkalemia, or muscular dystrophy is suspected.

Third-Line Continuous Anesthetic Infusions :

Continuous Midazolam Infusion : Loading dose 0.1 to 0.2 mg/kg 0.1\text{ to }0.2\text{ mg/kg} 0.1 to 0.2 mg/kg , followed by continuous infusion of 0.1 to 2.0 mg/kg/h 0.1\text{ to }2.0\text{ mg/kg/h} 0.1 to 2.0 mg/kg/h ( 1.5 to 33 mcg/kg/min 1.5\text{ to }33\text{ mcg/kg/min} 1.5 to 33 mcg/kg/min ).

Propofol Infusion : Loading dose 1 to 2 mg/kg 1\text{ to }2\text{ mg/kg} 1 to 2 mg/kg , followed by infusion of 2 to 5 mg/kg/h 2\text{ to }5\text{ mg/kg/h} 2 to 5 mg/kg/h .

High-Alert Warning : In children, prolonged infusions ( > 24 to 48 hours >24\text{ to }48\text{ hours} > 24 to 48 hours ) or high doses ( > 4 to 5 mg/kg/h >4\text{ to }5\text{ mg/kg/h} > 4 to 5 mg/kg/h ) carry a severe risk of Propofol Infusion Syndrome (PRIS) , characterized by severe refractory metabolic lactic acidosis, hyperkalemia, rhabdomyolysis, hepatomegaly, hyperlipidemia, renal failure, cardiac arrhythmias, and fatal myocardial collapse.

Thiopental / Pentobarbital : Barbiturate infusion ( 3 to 5 mg/kg 3\text{ to }5\text{ mg/kg} 3 to 5 mg/kg bolus, then 2 to 5 mg/kg/h 2\text{ to }5\text{ mg/kg/h} 2 to 5 mg/kg/h ). Potent myocardial depressant and peripheral vasodilator; necessitates invasive arterial line monitoring, central venous access, and concurrent vasopressor/inotropic support.

Continuous Electroencephalography (cEEG) :

Once neuromuscular blockade (e.g., rocuronium) is administered, motor convulsions cease, but electrographic seizure activity frequently persists unchecked ( non-convulsive status epilepticus ).

Continuous EEG telemetry is mandatory to detect electrographic status and titrate anesthetic infusions to achieve a target pattern of burst suppression (typically 10 to 15 seconds of electrical silence between bursts) maintained for 24 to 48 hours before gradual weaning.

Special Etiologies and Targeted Reversible Causes

Pyridoxine (Vitamin B6) Dependency :

In any neonate or infant under 12 months presenting with status epilepticus that fails to respond to benzodiazepines and standard anticonvulsants, suspect pyridoxine-dependent epilepsy (caused by mutations in ALDH7A1 encoding antiquitin).

Give pyridoxine 100 mg 100\text{ mg} 100 mg IV with EEG and cardiorespiratory monitoring and immediate airway/resuscitation support available: apnoea can occur. A clinical response supports suspicion but may be delayed and is not specific. Continue treatment while obtaining α-AASA/P6C testing and ALDH7A1 genetic confirmation.

Hyponatremic Seizures :

Seizures triggered by acute water intoxication, diluted infant formula, or inappropriate hypotonic IV fluids with serum sodium < 120 mmol/L <120\text{ mmol/L} < 120 mmol/L will not terminate with anticonvulsants alone.

Administer 3 % 3\% 3% Hypertonic Saline at 3 to 5 mL/kg 3\text{ to }5\text{ mL/kg} 3 to 5 mL/kg IV over 10 to 15 minutes. This rapidly raises serum sodium by 3 to 5 mmol/L 5\text{ mmol/L} 5 mmol/L , abating cerebral oedema and terminating seizure activity.